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Background: The synergistic combination of interferon (IFN) alpha-2b and IFN gamma results in more potent
in vitro biological effects mediated by both IFNs. The aim of this investigation was to evaluate by first time the
pharmacokinetics and pharmacodynamics of this combination in patients with mycosis fungoides.
Methods: An exploratory, prospective, open-label clinical trial was conducted. Twelve patients, both genders, 18 to
75 years-old, with mycosis fungoides at stages IB to III, were eligible for the study. All of them received
intramuscularly a single high dose (23 × 106 IU) of a novel synergistic IFN mixture (HeberPAGW) for pharmacokinetic
and pharmacodynamic studies. Serum IFN alpha-2b and IFN gamma concentrations were measured during
96 hours by commercial enzyme immunoassays (EIA) specific for each IFN. Other blood IFN-inducible markers and
laboratory variables were used as pharmacodynamics and safety criteria.
Results: The pharmacokinetic evaluation by EIA yielded a similar pattern for both IFNs that are also in agreement
with the well-known described profiles for these molecules when these are administered separately. The average
values for main parameters were: Cmax: 263 and 9.3 pg/mL; Tmax: 9.5 and 6.9 h; AUC: 4483 and 87.5 pg.h/mL,
half-life (t1/2): 4.9 and 13.4 h; mean residence time (MRT): 13.9 and 13.5 h, for serum IFN alpha-2b and IFN gamma,
respectively. The pharmacodynamic variables were strongly stimulated by simultaneous administration of both IFNs:
serum neopterin and beta-2 microglobulin levels (β2M), and stimulation of 2’-5’ oligoadenylate synthetase (OAS1)
mRNA expression. The most encouraging data was the high increment of serum neopterin, 8.0 ng/mL at 48 h, not
been described before for any unmodified or pegylated IFN. Additionally, β2M concentration doubled the pre-dose
value at 24–48 hours. For both variables the values remained clearly upper baseline levels at 96 hours.
Conclusions: HeberPAGWpossesses improved pharmacodynamic properties that may be very useful in the
oncologic setting. Efficacy trials can be carried out to confirm these findings.
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Similar to other low molecular weight protein drugs,
alpha or gamma interferons (IFNs) have a relatively
short serum half-life. Consequently, if vascular retention
is considered to be desired for enhanced efficacy, stra-
tegies that can improve a drug’s pharmacokinetic (PK)
and pharmacodynamic (PD) properties might improve
its therapeutic benefits. Novel injectable drug delivery
systems have been developed in attempts to improve
PK/PD properties of therapeutic peptides and proteins.
This can be achieved either by modification of the drug
molecule itself (e.g. pegylation) or through a change in
formulation (e.g. controlled-release formulations, liposo-
mal preparations) [1].
Another alternative is to potentiate the pharmaco-
dynamics of the therapeutic drug by the combination of
two active principles that can act synergistically. This
approach could have the same potential advantages of
novel delivery mechanisms that include an increased or
prolonged pharmacological activity without additional
toxicity, less frequent injections, and a better patient’s
compliance and quality of life.
IFNs have been widely used in the treatment of human
solid and hematological malignancies. However, despite
antitumor activity of IFNs is well-known at present, no
major advances have been achieved in the last decade. A
hopeful option could be the combination of IFN alpha-2b
and IFN gamma, two molecules with recognized synergis-
tic antiproliferative effects on several tumor cell lines [2].
Takaoka et al. demonstrated in mouse embryonic fibro-
blasts that IFN gamma response is substantially augmen-
ted through autocrine IFN alpha/beta. Additionally, they
observed that cross-recruitment and phosphorylation of
one of the IFN alpha/beta receptor subunits (IFNAR1)
occurred in response to IFN gamma [3]. Similarly, other
authors showed that IFNGR1-IFNAR2 (ligand binding
domains of both receptor systems) are associated in the
presence of IFN alpha and IFN gamma [4]. The physical
interaction between both IFN receptor complexes may be
the first step for the triggering of intracellular signals that
promote the synergism between both IFNs. In the clinics,
the peri- and intralesional administration of a new pharma-
ceutical stabilized formulation containing IFNs alpha-2b
and gamma (HeberPAGW), was safe and effective for the
treatment of elder patients with advanced, recurrent or
resistant to previous treatments basal and squamous cell
skin carcinomas [5].
The main objective of this study was to characterize
the PK/PD of HeberPAGW in patients with mycosis fun-
goides. Classical IFN-inducible biological markers, neop-
terin, β2-microglobulin (β2M), and 2’-5’ oligoadenylate
synthetase (2’-5’ OAS1), were used as indicators of their
pharmacodynamic action. A secondary objective was the
registration of adverse events.Methods
An exploratory, prospective, open-label clinical trial was
carried out at the “Hermanos Ameijeiras” Hospital,
Dermatology Service, Havana, Cuba. The protocol was
approved by the Ethics Committee of this hospital and
by the Cuban Regulatory Authority, the State Center for
the Control of Drugs, Equipment & Medical Devices
(CECMED, reference number: 999/16.016.09.B). The
trial was in compliance with the Helsinki Declaration
and its amendments. All patients prior to study enroll-
ment provided their written informed consent.Subjects
Twelve patients, both genders, 18 to 75 years-old, with
clinically and histologically proven mycosis fungoides, at
stages IB to III, were recruited for the study. Other eligi-
bility criteria included a measurable disease, a life expec-
tancy of at least 24 weeks, Karnofsky’s index ≥ 60%, with
more than 1 month of previous disease specific treatments
or more than 3 months in case of steroid use. Patients also
had adequate hematological, hepatic, and renal function.
Exclusion criteria were other uncompensated chronic
diseases or neoplasias, pregnancy or nursing and severe
psychiatric dysfunction.
HeberPAG formulation
A stabilized formulation containing 3.5 x106 IU of a sy-
nergistic combination of human recombinant, produced
in E. coli, IFNs alpha-2b and gamma (HeberPAGW,
Heber Biotec, Havana, Cuba), was used for all cases.
Each vial also contains 18.87 mg sodium phosphates,
13 mg Dextran-40, 0.24 mg kalium phosphate, 16.59 mg
sodium chloride, 0.18 mg kalium chloride, 5.0 mg mani-
tol, 5.0 mg saccharose, and 5.5 mg human albumin. This
lyophilized powder formulation was reconstituted with
2 mL bacteriostatic water for injection.
Study design
The study was designed to calculate pharmacokinetic
and pharmacodynamic parameters after a first single
high dose of HeberPAGW. Each patient received, intra-
muscularly, in the gluteus region, a single 23 x106 IU
HeberPAGW dose, chosen to obtain detectable serum
levels of both IFNs. Antipyretic medication was given
orally at the same time as the HeberPAGW injection and
every 4 hours thereafter, up to 12 hours or more if
needed in order to mitigate the expected IFN-dependent
flu-like syndrome. Patients were hospitalized during the
first 96 hours after the injection under strict medical
supervision. After this period the study continued to
evaluate efficacy and safety of this product in the same
group of patients. Then, they received 11 x106 IU twice
a week during one year.
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Blood samples for serum IFN alpha-2b and IFN
gamma concentration determinations were collected
by venipuncture before and 1, 3, 6, 12, 24, 48, 72,
and 96 hours after injection. Pharmacodynamics was
assessed by serum neopterin and β2M concentrations at
the same times and by the induction of 2’-5’ OAS1
mRNA expression before and at 6, 12, 24, 48, 72 and
96 hours. Routine hematological and biochemical deter-
minations were taken as safety variables, every 24 hours
during the first 96 hours. These included hemoglobin,
hematocrit, leukocytes and platelets counts, transami-
nases, bilirubin, creatinine and urea. Patients were regu-
larly checked for vital signs and symptoms during the
whole hospitalization.
Vacutainers were used to collect blood samples to de-
termine serum concentrations and biochemistry (8.5 mL
Z Serum Sep, Greiner bio-one) and for hematology
analysis (4 mL K3E K3EDTA, Greiner bio-one). Blood
samples for total RNA purification were collected in
PAXgene Blood RNA Tubes (2.5 mL, QIAGEN, US).
Serum IFNs, neopterin and β2M levels were measured
using commercially available kits according to the manu-
facturer’s instructions using sera stored at −80°C until be
tested. IFN alpha-2b and IFN gamma were quantified in
serum with high sensitivity enzyme immunoassay (EIA)
kits specific for IFN alpha (Catalogue: BMS216CE,
Bender MedSystem, GMBH) or IFN gamma (Catalogue:
BMS228CE, Bender MedSystem, GMBH), respectively.
Neopterin was determined by a commercial EIA kit
(HENNING test, BRAHMS Diagnostica GmbH, Berlin,
Germany) as well as serum β2M (Quantikine
W IVDW,
R&D System, Inc, Minneapolis).
Quantification of OAS1 mRNA levels was performed
using the Real-Time Polimerase Chain Reaction (qPCR)
method. Total RNAs were obtained by PAXgene puri-
fication protocol (PreAnalytiX/Qiagen, US). RNA quality
was checked in a Spectrophotometer Nanodrop 1000
(ThermoScientific, US), reporting a 260/280 nm OD rela-
tion between 1.7 and 2.2. Agarose electrophoresis allowed
to visualize 28S rRNA and 18S rRNA bands in a propor-
tion higher than 1.5. Complementary DNA (cDNA) was
used as template in qPCR experiments; the synthesis was
carried out using Superscript II RT kit and protocol
(Invitrogen, US) from total RNA samples at each time
point. qPCR experiments were performed in 20 μL using
ABsolute QPCR SYBR Green Mixes (ThermoScientific,
ABgene, UK) and 0.3 μM of primers for amplification of
OAS1 target gene (F: 5’ AGCCTCATCCGCCTAGTCAA
3’; R: 5’ CTCGCTCCCAAGCATAGACC 3’) and reference
genes GAPDH (F: 5’ CCATGGGTGGAATCATATTGGA
3’; R: 5’ TCAACGGATTTGGTCGTATTGG 3’) and HMBS
(F: 5’ GGAATGTTACGAGCAGTGATGC 3’; R: 5’
CCTGACTGGAGGAGTCTGGAGT 3’). All of them weredesigned on the basis of the GenBank database information
using primer3 software [6]. All experiments were in tripli-
cates, rendering amplifications curves between cycles 15
and 30 in RT™Cycler equipment (Capitalbio, China) with a
standard program of 15 min at 95°C for enzyme activation
followed by 40 cycles of 15 s at 95°C, 30s at 60°C and 30s at
72°C. Capitalbio software reports of Ct values, as the 2nd
derivative maximum, and values of fluorescence per cycle,
which were used for efficiency calculation by LinReg soft-
ware (version 11.3, 2009), were used for calculations of rela-
tive OAS1 gene expression, at each time point respect to
time 0 h, using REST-MCS (version 2, 2006) software [7],
after the normalization with reference genes.
Hematological counts and blood chemistry were done
according to usual clinical laboratory procedures, using
advanced automated analyzers.
Data analysis
The drug disposition data analysis was performed per pa-
tient by a non-compartmental method with a combined
linear/log - linear trapezoidal rule approach. The linear
trapezoidal rule was used up to peak level and the loga-
rithmic trapezoidal rule thereafter. The first-order rate
constant associated with the curve terminal (log linear)
portion (λ) and terminal half-life (t1/2) were estimated by
linear regression of the included terminal data points.
Time-to-peak values (Tmax) were determined directly
from the experimental data as the time of maximum
observed level (Cmax) considering the entire curve. Area
under the serum concentration-time curve from 0 to
96 hours (AUC96) was calculated using the linear/log
linear trapezoidal rule. Mean residence time (MRT) was
also calculated using the moments of the drug disposition
curve. Parameters that were extrapolated to infinity, such
as AUC (area under disposition curve) and AUMC (area
under first moment of the disposition curve) were com-
puted based on the last predicted value from the linear
regression performed to estimate λ and t1/2. Some similar
kinetic parameters were estimated for the pharmacody-
namic markers, corrected for baseline values, neopterin
and β2M in order to describe the kinetic behavior of the
IFN-induced immunological response: Rmax (maximum
response), T(Rmax) (time to reach maximum response),
λ effect (effect dissipation constant), t1/2 effect (effect
half-life), AUEC (area under the effect curve), MET
(mean effect time) [8]. The WinNonlin professional soft-
ware (Version 2.1, Pharsight Inc., 1997, NC, USA) was
used for all these purposes. A descriptive statistic was
done using SPSS for Windows version 15.0.
Results
Twelve patients, 7 females and 5 males, with a disease
stage IIA and III, were recruited. They were between 33
and 74 years-old (mean: 53.3 yrs), with a mean corporal
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variants of mycosis fungoides were represented; 6 patients
had plaques, 2 had erythroderma, and the rest had atypia
of the epidermis. Only five patients had received prior
systemic antitumor therapy, four of them IFN alpha and
three methotrexate. Other previous treatments (cyclospo-
rine, steroid cream, radiotherapy) were received by a
single patient each one. Initial mean LDH was 216 U/L
(range: 69 – 355). Most of the patients complied with the
evaluations as previewed, except for patient No.8 whose
serum samples were not available at 72 and 96 hours.
Pharmacokinetic analysis
Except for two patients, who had 7.1 and 114 pg/mL of
IFN alpha-2b, all had undetectable or very low endogenous
pre-dose serum IFN concentrations (median = 0 pg/ml).
The average concentration profiles obtained for both IFNs
are showed in Figure 1. IFN alpha-2b concentrations
started to increase notably from the first hour post-injec-
tion. At 3 hours, more than half of the patients reached
100 pg/mL. Maximum values (> 200 pg/mL) were obtained
at 6–12 hours in most of the cases (Figure 1a). Patient No.
12, who had the higher baseline value, reached 440 pg/mL









































Figure 1 Interferon concentrations in serum. Legend: Data correspond
HeberPAGW. Each point represents the average and standard deviation of (discreet with a peak at 12 hours post-injection, where
5 patients reached 15 pg/mL or more (Figure 1b). A pro-
nounced drop of IFN concentrations was detected since
24 hours. At 48–96 hours after the injection, these values
had returned near to the initial values, so the AUC96
obtained covered more than 95% of the AUC extrapolated
to infinite.
Table 1 shows the results of the pharmacokinetic para-
meters calculated from the above commented profiles. A
high patient -dependant variability is observed, mainly
with IFN gamma (see SD). Additionally, an elevated
distribution volume and fast blood clearance of both
IFNs was obtained (data not shown).
Pharmacodynamic analysis
The time courses for the induction of neopterin and
β2M are showed in Figure 2. Both variables were
strongly stimulated by simultaneous administration of
both IFNs with highest inductions around 24–48 hours
after intramuscular administration. HeberPAGW induced
an average increment of serum neopterin at 48 hours
about approximately six times, until 9.6 pg/mL com-
pared to pre-dose values (Figure 2a). Individually, five




to 12 patients with mycosis fungoides who received 23 × 106 IU of
a) IFN alpha-2b and (b) IFN gamma levels, both measured by EIA.
Table 1 Pharmacokinetic parameters calculated from the
IFN alpha-2b and IFN gamma concentrations in serum
(N = 12)
Parameter IFN alpha-2b IFN gamma
Cmax (pg/mL) 263 ± 129 9.3 ± 7.0
Tmax (h) 12.0 ± 6.0 6.0 ± 0.8
λ (h-1) 0.16 ± 0.06 0.07 ± 0.05
t1/2 (h) 4.9 ± 1.4 13.4 ± 27.1
AUC (pg.h/mL) 4483 ± 4485 87.5 ± 89.9
MRT (h) 13.9 ± 7.9 13.5 ± 8.2
Data are reported as mean ± standard deviation, except for Tmax expressed
as median ± quartile range.
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from baseline at 24–48 hours. For both variables the values
remained clearly upper baseline levels until 96 hours.
Notably, neopterin remained three times superior to pre-
dose value at the end of the sampling period.
A pharmacokinetic-like analytical procedure was carried
out with both variables (Table 2). Since patients could have
pre-treatment levels of these biological markers, a more real









































Figure 2 Pharmacodynamic markers neopterin and β2-microglobulin
fungoides who received 23 × 106 IU of HeberPAGW at time 0. (a): Average
concentration, measured by EIA. Standard deviations are also showed at eaover baseline. For neopterin Rmax was 8.0 ng/mL, with a
t1/2 effect = 40 hours and a MET around 80 hours. For
β2M, T(Rmax) was 2.7 μg/mL, and the effect dissipation
phase occurred similarly slow compared to neopterin. A
high intra-patient variability was again evidenced.
Since the individual induction of the enzyme 2’-5’ OAS1
was measured through the relative amount of its mRNA
expression using the Real-Time PCR method, an impor-
tant variability could be expected. Therefore, parameters
could not be rigorously calculated from the experimental
data and the analysis was essentially qualitative. Figure 3
shows individual relative OAS1 mRNA levels at each time
point with respect to time zero, normalized with GAPDH/
HMBS levels. A single intramuscular dose of 23 x106 IU
of HeberPAGW resulted in high increases of this variable
with regard to their pre-dose values in all patients, in a
factor between 8 and 122 times in ten patients, primarily
within the first 24 hours after dosing. The expression
levels return to initials by 96 hours in most of the patients.
Safety data
Adverse events were checked during the whole study. All




in serum. Legend: Data correspond to 12 patients with mycosis
neopterin concentration, measured by EIA. (b): Average β2M
ch time.
Table 2 Descriptive parameters of the kinetics of serum
Neopterin and serum β2-microglobulin increments
(N = 12)
Parameter Neopterin β2-microglobulin
Rmax 8.0 ± 4.2 ng/mL 2.7 ± 1.4 μg/mL
T(Rmax) 48 ± 24 h 24 ± 24 h
λ effect 0.02 ± 0.01 h-1 0.02 ± 0.01 h-1
t1/2 effect 40.3 ± 12.9 h 37.6 ± 15.9 h
AUEC 661 ± 322 ng.h/mL 195 ± 117 μg.h/mL
MET 80.6 ± 17.4 h 74.8 ± 21.9 h
Data are reported as mean ± standard deviation, except for T(Rmax) expressed
































































Figure 3 Individual relative 2’-5’ OAS1 mRNA expression. Legend: Data
23 × 106 IU of HeberPAGW at time 0. Each point represents the relative amo
each time respect to time 0, after the normalization with reference genes G
their very high specific mRNA expression.
García-Vega et al. BMC Pharmacology and Toxicology 2012, 13:20 Page 6 of 9
http://www.biomedcentral.com/2050-6511/13/20symptoms caused by IFN. The most frequent events were
fever (100%), malaise (91.7%), headache (58.3%), tachycar-
dia (41.6%), leucopenia (33.3%), chills (33.3%) and anemia
(25%). Anorexia, arthralgias, increase of transaminases and
myalgias were recorded in two patients. Most of the events
(92.3%) were considered mild, none severe, being well
controlled.
Discussion
Treatment with unmodified IFNs for several malignancies
and chronic viral affections requires frequent injections
(e.g., daily or three times weekly) over the course of therapy
due to the molecule’s short circulating half-life in humans.
Increase of doses and prolonged therapy could favor a bet-
ter clinical response but it could also lead to magnify ad-
verse events. Besides, patient’s compliance under long-term




































correspond to 12 patients with mycosis fungoides who received
unt and its associated standard error of OAS1 gene expression at
APDH and HMBS. Patients No. 1 and 12 are separately graphed since
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frequency and to enhance response rates in patients with
chronic hepatitis C [9]. However, modified high molecular
IFNs could have more difficulties to penetrate the tumor
niches bearing a reduction in their antitumor effects. A sig-
nificant reduction of in vitro biological activity has been
demonstrated for pegylated IFNs due to non optimal inter-
action with IFN receptor [10].
Therefore sustained full IFN-receptor interactions with
more potent antiproliferative activity are desired in the
treatment of cancer. This is possible to obtain combining
IFN-alpha and IFN gamma that synergize for their bio-
logical activities. HeberPAGW is a new formulation con-
taining a mixture of recombinant IFN alpha-2b and IFN
gamma at synergistic proportions. This formulation was
created to improve antiproliferative and other biological
effects of conventional IFNs with an adequate tolerability
leading to administer fewer doses similar to others cur-
rently available therapy. This is the first PK/PD study in
humans with this variety of IFN formulation.
The pharmacodynamic variables measured in this trial to
characterize HeberPAGW formulation are well-known IFN-
induced genes, classical surrogate markers of IFN bio-
logical actions. Neopterin is a sensitive marker of T helper
1-cell immune response, because it is primarily produced
by monocytes/macrophages after activation by IFNs and
augments the production of tumor necrosis factor in per-
ipheral blood mononuclear cells [11]. Beta2-microglobulin
plays an important role in the tumor growth control and
metastases [12]. Progression of the cell cycle is mediated
by 2’- 5’OAS levels stimulated by IFN [13]. Additionally,
antiviral effects subsequent to IFNs addition are initiated
by synthesis of 2’- 5’oligoadenylates that activate an endori-
bonuclease to cleave double-stranded viral RNA [14].
The most remarkable result was the six-fold increase of
serum neopterin concentrations respect to basal value.
This high increment induced by HeberPAGW has not
been described before in the literature with any subtype
or variant of IFN, even for pegylated forms [15-20]. The
induction by pegylated IFN-alpha could only approxi-
mately tripled the neopterin basal values as maximum
48 hours after injection as reported [17,19,20]. In the case
of PEG-IFN beta although half-life was greatly extended
by pegylation, the neopterin response was not affected
[18]. On the other hand, two times higher levels than
baseline were recorded for serum β2M 24–48 hours after
injection, superior to those increments detected by other
authors, which were around 60% with natural or pegy-
lated IFN-alpha [19-21]. For both pharmacodynamic
markers their more slow return to initial levels has not
been observed with conventional IFN in the reports
above-cited. This last result could lead to space the dosage
interval for the IFN mixture formulation until twice or
once a week. Recent data obtained with the same markersbut in healthy male volunteers [article in preparation]
emphasize that possibility. Efficacy trials evaluating these
frequencies of administration in several oncologic path-
ologies are under development.
After the single intramuscular injection, 2’- 5’-OAS1
mRNA levels were extensively increased which was also
recently found in a group of healthy male volunteers who
received 24.5 × 106 IU of a similar formulation. Although
mRNA induction does not ensure the presence of active
protein, it has been reported that 2’-5’ OAS enzyme acti-
vity in the serum of IFN-treated patients appears to
increase since the first 6 hours and maintains elevated
levels for as long as 4 to 8 months after the initiation of
daily IFN treatment [22].
At molecular level this beneficial pharmacodynamic
effects could be explained by synergistic effects in the
expression and activation of several genes regulated by
both IFNs [23].
Concerning pharmacokinetics, no interferences by
simultaneous administered IFNs were observed in their
typical similar serum profiles. Parameters as Tmax and
t1/2 were within the reported ranges for these conven-
tional IFNs after systemic administration either in
patients or healthy volunteers even considering the
expected high variability [24-27]. For IFN alpha-2b
Cmax was also very similar to a previous report ours in
healthy male volunteers [21].
Flu-like symptoms and other clinical and laboratory
adverse events associated with HeberPAGW have been
previously reported for recombinant IFN treatment [28].
Fever began 2 to 4 hours after intramuscular adminis-
tration and peaked at 6 to 12 hours coincident with
maximum IFN serum levels. However, the mechanisms
of fever induction appear to be different between IFNs.
IFN-alpha has been shown to be intrinsically pyrogenic
and the body temperature rise is related to the inter-
action of IFN alpha to hypothalamic μ-opioid receptors
[29]. Meanwhile the administration of IFN gamma
stimulates the release of other lymphokines such as
interleukin-1 [30], an endogenous pyrogen [31].
Conclusion
The co-administration of IFN alpha-2b and IFN gamma
with potent synergistic actions will allow us to obtain a
more favorable pharmacodynamics introducing new
promissory perspectives in the use of IFNs to treat
several malignancies. Efficacy trials can be carried out to
ratify the obtained results.
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